Group 1: Financial Performance - In 2024, the company achieved a revenue of 641 million CNY, representing a growth of 10.23% compared to the previous year [4] - The net profit attributable to shareholders was 91.83 million CNY, an increase of 7.24% year-on-year [4] - R&D expenses for 2024 amounted to 23.98 million CNY, accounting for 3.74% of total revenue [3] Group 2: Product Development and Innovation - The company launched new products including "民生普瑞宝益生菌冻干粉" and "民生普瑞宝即食益生菌" [2] - In 2024, the company added 1 new drug approval, 3 invention patents, and 4 utility model patents [3] - The company is developing a new series of composite nutrient supplements, currently at various stages of R&D [6] Group 3: Market Strategy and Sales - The company reported a 23.69% revenue growth in the Central China region, attributed to targeted market strategies [5] - The vitamin and mineral supplement series saw a revenue increase of 10.47% in 2024 [6] - The company is expanding its e-commerce presence on platforms like Tmall, JD.com, and Douyin [7] Group 4: Strategic Partnerships and Collaborations - The strategic partnership with 中科嘉亿 aims to enhance the company's capabilities in the probiotics sector [4] - The company is leveraging its collaboration to expand its product offerings and market reach in the probiotics field [4] Group 5: Future Outlook and Plans - The company plans to cultivate multiple star products as part of its 2025 operational strategy [5] - Future initiatives include enhancing digital transformation and smart manufacturing to improve efficiency [3] - The company aims to explore international markets and introduce its products globally [6]
民生健康(301507) - 投资者关系活动记录表2025-003